# Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels

> **NCT01889160** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 44 (actual)

## Conditions studied

- Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax

## Interventions

- **DRUG:** AZD4721 Solution
- **DRUG:** AZD4721 Placebo
- **DRUG:** AZD4721 Suspension

## Key facts

- **NCT ID:** NCT01889160
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2015-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01889160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01889160, "Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01889160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*